Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ono-7579
- Development stage
- Preclinical
- Lead developer
- Ono Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ONO-7579 is an orally bioavailable, selective pan-tropomyosin receptor kinase (TRK) inhibitor developed as a potential antineoplastic agent. It specifically targets and binds to TRK proteins and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1/TrkA), 2 (NTRK2/TrkB), and 3 (NTRK3/TrkC). By inhibiting the interaction between neurotrophins and TRKs, ONO-7579 blocks downstream signaling pathways that promote tumor cell growth, survival, invasion, and resistance to treatment. This leads to induction of apoptosis and inhibition of proliferation in tumors overexpressing TRKs or expressing NTRK fusion proteins. The drug is under investigation for use in advanced solid tumors with NTRK gene fusions[1][2][4][7].
- Other names
- 1-[2-[4-(2-amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl]-3-[2-methylsulfonyl-5-(trifluoromethyl)phenyl]urea
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on ono-7579.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ono-7579.